4.5 Article

Impact of immunization against SpyCEP during invasive disease with two streptococcal species: Streptococcus pyogenes and Streptococcus equi

期刊

VACCINE
卷 27, 期 36, 页码 4923-4929

出版社

ELSEVIER SCI LTD
DOI: 10.1016/j.vaccine.2009.06.042

关键词

Streptococcus pyogenes; SpyCEP; Vaccine

资金

  1. Wellcome Trust
  2. UK NIHR Biomedical Research Centre
  3. Lee Spark Foundation
  4. Hammersmith Hospital Trustees Research Committee
  5. Biotechnology and Biological Sciences Research Council [BB/E52708X/1] Funding Source: researchfish
  6. Medical Research Council [G0800777] Funding Source: researchfish
  7. BBSRC [BB/E52708X/1] Funding Source: UKRI
  8. MRC [G0800777] Funding Source: UKRI

向作者/读者索取更多资源

Currently there is no licensed vaccine against the human pathogen Streptococcus pyogenes. The highly conserved IL-8 cleaving S. pyogenes cell envelope proteinase SpyCEP is surface expressed and is a potential vaccine candidate. A recombinant N-terminal part of SpyCEP (CEP) was expressed and purified. AntiCEP antibodies were found to neutralize the IL-8 cleaving activity of SpyCEP. CEP-immunized mice had reduced bacterial dissemination from focal S. pyogenes intramuscular infection and intranasal infection. We also identified a functional SpyCEP-homolog protease SeCEP, expressed by the equine pathogen Streptococcus equi, which was able to cleave both human and equine IL-8. CEP-immunized mice also demonstrated reduced bacterial dissemination from S. equi intramuscular infection. Therefore immunization against SpyCEP may provide protection against other streptococci species with homologous proteases. (C) 2009 Elsevier Ltd. All rights reserved.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.5
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据